These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 22298405)

  • 1. Compressed opiate withdrawal syndrome and naltrexone.
    Farrell M; Strang J
    J Psychopharmacol; 1995 Jan; 9(4):383-5. PubMed ID: 22298405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
    Lubman D; Koutsogiannis Z; Kronborg I
    Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral activation induced by D(2)-like receptor stimulation during opiate withdrawal.
    Druhan JP; Walters CL; Aston-Jones G
    J Pharmacol Exp Ther; 2000 Aug; 294(2):531-8. PubMed ID: 10900229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome.
    Bearn J; Bennett J; Martin T; Gossop M; Strang J
    Addict Biol; 2001 Apr; 6(2):147-156. PubMed ID: 11341854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.
    Mannelli P; Gottheil E; Peoples JF; Oropeza VC; Van Bockstaele EJ
    Biol Psychiatry; 2004 Aug; 56(4):261-8. PubMed ID: 15312814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ultra-rapid opiate detoxification on withdrawal syndrome.
    Safari F; Mottaghi K; Malek S; Salimi A
    J Addict Dis; 2010 Oct; 29(4):449-54. PubMed ID: 20924880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ultra-rapid detoxification of opiate dependent patients: review of the literature, critiques and proposition for an experimental protocol].
    Fontaine E; Godfroid IO; Guillaume R
    Encephale; 2001; 27(2):187-93. PubMed ID: 11407272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
    Johnson F; Setnik B
    Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats.
    Van Bockstaele EJ; Rudoy C; Mannelli P; Oropeza V; Qian Y
    J Neurosci Res; 2006 Feb; 83(3):508-14. PubMed ID: 16385558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sequential use of clonidine and naltrexone in the treatment of opiate addicts.
    Gold MS; Dackis CA; Washton AM
    Adv Alcohol Subst Abuse; 1984; 3(3):19-39. PubMed ID: 6388273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonist treatment of opioid withdrawal translational low dose approach.
    Mannelli P; Gottheil E; Van Bockstaele EJ
    J Addict Dis; 2006; 25(2):1-8. PubMed ID: 16785213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-rapid opiate detoxification followed by nine months of naltrexone maintenance therapy in Iran.
    Naderi-Heiden A; Naderi A; Naderi MM; Rahmani-Didar F; Salimi AR; Gleiss A; Kasper S; Frey R
    Pharmacopsychiatry; 2010 Jun; 43(4):130-7. PubMed ID: 20101570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminative stimulus effects of morphine withdrawal in the dependent rat: suppression by opiate and nonopiate drugs.
    Holtzman SG
    J Pharmacol Exp Ther; 1985 Apr; 233(1):80-6. PubMed ID: 4039002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures.
    Carreño JE; Bobes J; Brewer C; Alvarez CE; San Narciso GI; Bascarán MT; Sánchez del Río J
    Addict Biol; 2002 Apr; 7(2):243-50. PubMed ID: 12006220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.
    Tempel A; Gardner EL; Zukin RS
    J Pharmacol Exp Ther; 1985 Feb; 232(2):439-44. PubMed ID: 2982011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A compressed opiate detoxification regime with naltrexone maintenance: patient tolerance, risk assessment and abstinence rates.
    Beaini AY; Johnson TS; Langstaff P; Carr MP; Crossfield JN; Sweeney RC
    Addict Biol; 2000 Oct; 5(4):451-62. PubMed ID: 20575864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of very low-dose naltrexone during opiate detoxification.
    Mannelli P; Gottheil E; Buonanno A; De Risio S
    J Addict Dis; 2003; 22(2):63-70. PubMed ID: 12703669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
    Gold MS
    Psychiatr Clin North Am; 1993 Mar; 16(1):61-73. PubMed ID: 8456048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome.
    de Wet C; Reed L; Glasper A; Moran P; Bearn J; Gossop M
    Drug Alcohol Depend; 2004 Oct; 76(1):31-5. PubMed ID: 15380286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.